{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:46:37Z","timestamp":1790775997414,"version":"4.1.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["13OCA27"],"award-info":[{"award-number":["13OCA27"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00467-018-4042-z","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T07:38:05Z","timestamp":1535009885000},"page":"1349-1367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0750-4493","authenticated-orcid":false,"given":"Marloes A. H. M.","family":"Michels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena B.","family":"Volokhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus P. W. J.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"4042_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneph.2016.70","volume":"12","author":"D Ricklin","year":"2016","unstructured":"Ricklin D, Reis ES, Lambris JD (2016) Complement in disease: a defence system turning offensive. Nat Rev Nephrol 12:383\u2013401","journal-title":"Nat Rev Nephrol"},{"key":"4042_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","volume":"14","author":"D Ricklin","year":"2018","unstructured":"Ricklin D, Mastellos DC, Reis ES, Lambris JD (2018) The renaissance of complement therapeutics. Nat Rev Nephrol 14:26\u201347","journal-title":"Nat Rev Nephrol"},{"key":"4042_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785\u2013797","journal-title":"Nat Immunol"},{"key":"4042_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","volume":"33","author":"M Noris","year":"2013","unstructured":"Noris M, Remuzzi G (2013) Overview of complement activation and regulation. Semin Nephrol 33:479\u2013492","journal-title":"Semin Nephrol"},{"key":"4042_CR5","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.4049\/jimmunol.151.5.2521","volume":"151","author":"W Schwaeble","year":"1993","unstructured":"Schwaeble W, Dippold WG, Schafer MK, Pohla H, Jonas D, Luttig B, Weihe E, Huemer HP, Dierich MP, Reid KB (1993) Properdin, a positive regulator of complement activation, is expressed in human T cell lines and peripheral blood T cells. J Immunol 151:2521\u20132528","journal-title":"J Immunol"},{"key":"4042_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1084\/jem.151.3.501","volume":"151","author":"K Whaley","year":"1980","unstructured":"Whaley K (1980) Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med 151:501\u2013516","journal-title":"J Exp Med"},{"key":"4042_CR7","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.4049\/jimmunol.180.5.3313","volume":"180","author":"CM Stover","year":"2008","unstructured":"Stover CM, Luckett JC, Echtenacher B, Dupont A, Figgitt SE, Brown J, Mannel DN, Schwaeble WJ (2008) Properdin plays a protective role in polymicrobial septic peritonitis. J Immunol 180:3313\u20133318","journal-title":"J Immunol"},{"key":"4042_CR8","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.4049\/jimmunol.158.9.4444","volume":"158","author":"U Wirthmueller","year":"1997","unstructured":"Wirthmueller U, Dewald B, Thelen M, Schafer MK, Stover C, Whaley K, North J, Eggleton P, Reid KB, Schwaeble WJ (1997) Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J Immunol 158:4444\u20134451","journal-title":"J Immunol"},{"key":"4042_CR9","doi-asserted-by":"publisher","unstructured":"Tsyrkunou A, Agarwal S, Koirala B, Finberg RW, Nath R, Barton B, Levitz SM, Wang JP, Ram S (2017) Properdin levels in individuals with chemotherapy-induced neutropenia. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofw250","DOI":"10.1093\/ofid\/ofw250"},{"key":"4042_CR10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4049\/jimmunol.142.1.202","volume":"142","author":"MK Pangburn","year":"1989","unstructured":"Pangburn MK (1989) Analysis of the natural polymeric forms of human properdin and their functions in complement activation. J Immunol 142:202\u2013207","journal-title":"J Immunol"},{"key":"4042_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/cei.12754","volume":"184","author":"F Corvillo","year":"2016","unstructured":"Corvillo F, Bravo Garcia-Morato M, Nozal P, Garrido S, Tortajada A, Rodriguez de Cordoba S, Lopez-Trascasa M (2016) Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. Clin Exp Immunol 184:118\u2013125","journal-title":"Clin Exp Immunol"},{"key":"4042_CR12","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.2215\/CJN.01820214","volume":"9","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ (2014) Defining the complement biomarker profile of C3 glomerulopathy. Clin J Am Soc Nephrol 9:1876\u20131882","journal-title":"Clin J Am Soc Nephrol"},{"key":"4042_CR13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/j.ajkd.2017.07.004","volume":"70","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Meyer NC, Fervenza FC, Lau W, Keenan A, Cara-Fuentes G, Shao D, Akber A, Fremeaux-Bacchi V, Sethi S, Nester CM, Smith RJH (2017) C4 nephritic factors in C3 glomerulopathy: a case series. Am J Kidney Dis 70:834\u2013843","journal-title":"Am J Kidney Dis"},{"key":"4042_CR14","first-page":"24","volume":"6","author":"CM Stover","year":"2015","unstructured":"Stover CM, McDonald J, Byrne S, Lambert DG, Thompson JP (2015) Properdin levels in human sepsis. Front Immunol 6:24","journal-title":"Front Immunol"},{"key":"4042_CR15","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2337\/dc11-1483","volume":"35","author":"R Somani","year":"2012","unstructured":"Somani R, Richardson VR, Standeven KF, Grant PJ, Carter AM (2012) Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes. Diabetes Care 35:894\u2013899","journal-title":"Diabetes Care"},{"key":"4042_CR16","doi-asserted-by":"publisher","first-page":"42532","DOI":"10.1038\/srep42532","volume":"7","author":"N Shahini","year":"2017","unstructured":"Shahini N, Michelsen AE, Nilsson PH, Ekholt K, Gullestad L, Broch K, Dahl CP, Aukrust P, Ueland T, Mollnes TE, Yndestad A, Louwe MC (2017) The alternative complement pathway is dysregulated in patients with chronic heart failure. Sci Rep 7:42532","journal-title":"Sci Rep"},{"key":"4042_CR17","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.4049\/jimmunol.180.11.7613","volume":"180","author":"W Xu","year":"2008","unstructured":"Xu W, Berger SP, Trouw LA, de Boer HC, Schlagwein N, Mutsaers C, Daha MR, van Kooten C (2008) Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J Immunol 180:7613\u20137621","journal-title":"J Immunol"},{"key":"4042_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12967-016-0995-5","volume":"14","author":"F Poppelaars","year":"2016","unstructured":"Poppelaars F, Gaya da Costa M, Berger SP, Assa S, Meter-Arkema AH, Daha MR, van Son WJ, Franssen CF, Seelen MA (2016) Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med 14:236","journal-title":"J Transl Med"},{"key":"4042_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1046\/j.1365-3083.2003.01326.x","volume":"58","author":"PF Paula de","year":"2003","unstructured":"de Paula PF, Barbosa JE, Junior PR, Ferriani VP, Latorre MR, Nudelman V, Isaac L (2003) Ontogeny of complement regulatory proteins - concentrations of factor h, factor I, c4b-binding protein, properdin and vitronectin in healthy children of different ages and in adults. Scand J Immunol 58:572\u2013577","journal-title":"Scand J Immunol"},{"key":"4042_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/sji.12154","volume":"79","author":"AS Grumach","year":"2014","unstructured":"Grumach AS, Ceccon ME, Rutz R, Fertig A, Kirschfink M (2014) Complement profile in neonates of different gestational ages. Scand J Immunol 79:276\u2013281","journal-title":"Scand J Immunol"},{"key":"4042_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ki.2012.313","volume":"83","author":"SJ Gou","year":"2013","unstructured":"Gou SJ, Yuan J, Chen M, Yu F, Zhao MH (2013) Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 83:129\u2013137","journal-title":"Kidney Int"},{"key":"4042_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jcla.20154","volume":"21","author":"K Onda","year":"2007","unstructured":"Onda K, Ohi H, Tamano M, Ohsawa I, Wakabayashi M, Horikoshi S, Fujita T, Tomino Y (2007) Hypercomplementemia in adult patients with IgA nephropathy. J Clin Lab Anal 21:77\u201384","journal-title":"J Clin Lab Anal"},{"key":"4042_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/0090-1229(76)90152-5","volume":"5","author":"JO Minta","year":"1976","unstructured":"Minta JO, Jezyk PD, Lepow IH (1976) Distribution and levels of properdin in human body fluids. Clin Immunol Immunopathol 5:84\u201390","journal-title":"Clin Immunol Immunopathol"},{"key":"4042_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s100249900016","volume":"1","author":"J Sonntag","year":"1998","unstructured":"Sonntag J, Brandenburg U, Polzehl D, Strauss E, Vogel M, Dudenhausen JW, Obladen M (1998) Complement system in healthy term newborns: reference values in umbilical cord blood. Pediatr Dev Pathol 1:131\u2013135","journal-title":"Pediatr Dev Pathol"},{"key":"4042_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1203\/00006450-197909000-00019","volume":"13","author":"CA Davis","year":"1979","unstructured":"Davis CA, Vallota EH, Forristal J (1979) Serum complement levels in infancy: age related changes. Pediatr Res 13:1043\u20131046","journal-title":"Pediatr Res"},{"key":"4042_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1651-2227.1997.tb08924.x","volume":"86","author":"B Wolach","year":"1997","unstructured":"Wolach B, Dolfin T, Regev R, Gilboa S, Schlesinger M (1997) The development of the complement system after 28 weeks\u2019 gestation. Acta Paediatr Scand 86:523\u2013527","journal-title":"Acta Paediatr Scand"},{"key":"4042_CR27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/j.1651-2227.1987.tb17268.x","volume":"76","author":"K Prellner","year":"1987","unstructured":"Prellner K, Sjoholm AG, Truedsson L (1987) Concentrations of C1q, factor B, factor D and properdin in healthy children, and the age-related presence of circulating C1r-C1s complexes. Acta Paediatr Scand 76:939\u2013943","journal-title":"Acta Paediatr Scand"},{"key":"4042_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000241276","volume":"37","author":"JH Drew","year":"1980","unstructured":"Drew JH, Arroyave CM (1980) The complement system of the newborn infant. Biol Neonate 37:209\u2013217","journal-title":"Biol Neonate"},{"key":"4042_CR29","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1016\/S0021-9258(17)43086-9","volume":"259","author":"CA Smith","year":"1984","unstructured":"Smith CA, Pangburn MK, Vogel CW, Muller-Eberhard HJ (1984) Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J Biol Chem 259:4582\u20134588","journal-title":"J Biol Chem"},{"key":"4042_CR30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/eji.1830210333","volume":"21","author":"KF Nolan","year":"1991","unstructured":"Nolan KF, Schwaeble W, Kaluz S, Dierich MP, Reid KB (1991) Molecular cloning of the cDNA coding for properdin, a positive regulator of the alternative pathway of human complement. Eur J Immunol 21:771\u2013776","journal-title":"Eur J Immunol"},{"key":"4042_CR31","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.4049\/jimmunol.155.12.5777","volume":"155","author":"JM Higgins","year":"1995","unstructured":"Higgins JM, Wiedemann H, Timpl R, Reid KB (1995) Characterization of mutant forms of recombinant human properdin lacking single thrombospondin type I repeats. Identification of modules important for function. J Immunol 155:5777\u20135785","journal-title":"J Immunol"},{"key":"4042_CR32","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.jmb.2004.09.001","volume":"343","author":"Z Sun","year":"2004","unstructured":"Sun Z, Reid KB, Perkins SJ (2004) The dimeric and trimeric solution structures of the multidomain complement protein properdin by X-ray scattering, analytical ultracentrifugation and constrained modelling. J Mol Biol 343:1327\u20131343","journal-title":"J Mol Biol"},{"key":"4042_CR33","doi-asserted-by":"publisher","first-page":"13504","DOI":"10.1073\/pnas.1309618110","volume":"110","author":"M Alcorlo","year":"2013","unstructured":"Alcorlo M, Tortajada A, Rodriguez de Cordoba S, Llorca O (2013) Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin. Proc Natl Acad Sci U S A 110:13504\u201313509","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4042_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/mab.2014.0066","volume":"34","author":"P Bertram","year":"2015","unstructured":"Bertram P, Akk AM, Zhou HF, Mitchell LM, Pham CT, Hourcade DE (2015) Anti-mouse properdin TSR 5\/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis. Monoclon Antib Immunodiagn Immunother 34:1\u20136","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"4042_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0167-4838(01)00238-2","volume":"1548","author":"MV Perdikoulis","year":"2001","unstructured":"Perdikoulis MV, Kishore U, Reid KB (2001) Expression and characterisation of the thrombospondin type I repeats of human properdin. Biochim Biophys Acta 1548:265\u2013277","journal-title":"Biochim Biophys Acta"},{"key":"4042_CR36","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.15252\/embj.201696173","volume":"36","author":"DV Pedersen","year":"2017","unstructured":"Pedersen DV, Roumenina L, Jensen RK, Gadeberg TA, Marinozzi C, Picard C, Rybkine T, Thiel S, Sorensen UB, Stover C, Fremeaux-Bacchi V, Andersen GR (2017) Functional and structural insight into properdin control of complement alternative pathway amplification. EMBO J 36:1084\u20131099","journal-title":"EMBO J"},{"key":"4042_CR37","first-page":"262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT (2015) Complement system part I - molecular mechanisms of activation and regulation. Front Immunol 6:262","journal-title":"Front Immunol"},{"key":"4042_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","volume":"38","author":"M Harboe","year":"2004","unstructured":"Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE (2004) The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol 38:439\u2013446","journal-title":"Clin Exp Immunol"},{"key":"4042_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1126\/science.120.3112.279","volume":"120","author":"L Pillemer","year":"1954","unstructured":"Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC (1954) The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120:279\u2013285","journal-title":"Science"},{"key":"4042_CR40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/BF02918255","volume":"12","author":"KK Maves","year":"1993","unstructured":"Maves KK, Weiler JM (1993) Properdin: approaching four decades of research. Immunol Res 12:233\u2013243","journal-title":"Immunol Res"},{"key":"4042_CR41","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1042\/bj2350723","volume":"235","author":"MK Pangburn","year":"1986","unstructured":"Pangburn MK, Muller-Eberhard HJ (1986) The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J 235:723\u2013730","journal-title":"Biochem J"},{"key":"4042_CR42","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1084\/jem.144.4.1076","volume":"144","author":"RG Medicus","year":"1976","unstructured":"Medicus RG, Gotze O, Muller-Eberhard HJ (1976) Alternative pathway of complement: recruitment of precursor properdin by the labile C3\/C5 convertase and the potentiation of the pathway. J Exp Med 144:1076\u20131093","journal-title":"J Exp Med"},{"key":"4042_CR43","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1084\/jem.142.4.856","volume":"142","author":"DT Fearon","year":"1975","unstructured":"Fearon DT, Austen KF (1975) Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med 142:856\u2013863","journal-title":"J Exp Med"},{"key":"4042_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1042\/bj2520047","volume":"252","author":"TC Farries","year":"1988","unstructured":"Farries TC, Lachmann PJ, Harrison RA (1988) Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products. Biochem J 252:47\u201354","journal-title":"Biochem J"},{"key":"4042_CR45","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1042\/bj2530667","volume":"253","author":"TC Farries","year":"1988","unstructured":"Farries TC, Lachmann PJ, Harrison RA (1988) Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement. Biochem J 253:667\u2013675","journal-title":"Biochem J"},{"key":"4042_CR46","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1074\/jbc.M508928200","volume":"281","author":"DE Hourcade","year":"2006","unstructured":"Hourcade DE (2006) The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Biol Chem 281:2128\u20132132","journal-title":"J Biol Chem"},{"key":"4042_CR47","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.4049\/jimmunol.1600040","volume":"196","author":"AZ Blatt","year":"2016","unstructured":"Blatt AZ, Saggu G, Kulkarni KV, Cortes C, Thurman JM, Ricklin D, Lambris JD, Valenzuela JG, Ferreira VP (2016) Properdin-mediated C5a production enhances stable binding of platelets to granulocytes in human whole blood. J Immunol 196:4671\u20134680","journal-title":"J Immunol"},{"key":"4042_CR48","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","volume":"92","author":"MC Marinozzi","year":"2017","unstructured":"Marinozzi MC, Chauvet S, Le Quintrec M, Mignotet M, Petitprez F, Legendre C, Cailliez M, Deschenes G, Fischbach M, Karras A, Nobili F, Pietrement C, Dragon-Durey MA, Fakhouri F, Roumenina LT, Fremeaux-Bacchi V (2017) C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney Int 92:1232\u20131241","journal-title":"Kidney Int"},{"key":"4042_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12915-015-0203-8","volume":"13","author":"ET Berends","year":"2015","unstructured":"Berends ET, Gorham RD Jr, Ruyken M, Soppe JA, Orhan H, Aerts PC, de Haas CJ, Gros P, Rooijakkers SH (2015) Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes. BMC Biol 13:93","journal-title":"BMC Biol"},{"key":"4042_CR50","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.4049\/jimmunol.1401814","volume":"194","author":"U Jain","year":"2015","unstructured":"Jain U, Cao Q, Thomas NA, Woodruff TM, Schwaeble WJ, Stover CM, Stadnyk AW (2015) Properdin provides protection from Citrobacter rodentium-induced intestinal inflammation in a C5a\/IL-6-dependent manner. J Immunol 194:3414\u20133421","journal-title":"J Immunol"},{"key":"4042_CR51","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1097\/MIB.0000000000000398","volume":"21","author":"U Jain","year":"2015","unstructured":"Jain U, Midgen CA, Schwaeble WJ, Stover CM, Stadnyk AW (2015) Properdin regulation of complement activation affects colitis in interleukin 10 gene-deficient mice. Inflamm Bowel Dis 21:1519\u20131528","journal-title":"Inflamm Bowel Dis"},{"key":"4042_CR52","doi-asserted-by":"publisher","first-page":"R173","DOI":"10.1186\/ar3926","volume":"14","author":"P Dimitrova","year":"2012","unstructured":"Dimitrova P, Ivanovska N, Belenska L, Milanova V, Schwaeble W, Stover C (2012) Abrogated RANKL expression in properdin-deficient mice is associated with better outcome from collagen-antibody-induced arthritis. Arthritis Res Ther 14:R173","journal-title":"Arthritis Res Ther"},{"key":"4042_CR53","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.molimm.2010.02.007","volume":"47","author":"P Dimitrova","year":"2010","unstructured":"Dimitrova P, Ivanovska N, Schwaeble W, Gyurkovska V, Stover C (2010) The role of properdin in murine zymosan-induced arthritis. Mol Immunol 47:1458\u20131466","journal-title":"Mol Immunol"},{"key":"4042_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1681\/ASN.2012060571","volume":"24","author":"MM Ruseva","year":"2013","unstructured":"Ruseva MM, Vernon KA, Lesher AM, Schwaeble WJ, Ali YM, Botto M, Cook T, Song W, Stover CM, Pickering MC (2013) Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J Am Soc Nephrol 24:43\u201352","journal-title":"J Am Soc Nephrol"},{"key":"4042_CR55","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.kint.2016.11.018","volume":"91","author":"AL Williams","year":"2017","unstructured":"Williams AL, Gullipalli D, Ueda Y, Sato S, Zhou L, Miwa T, Tung KS, Song WC (2017) C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy. Kidney Int 91:1386\u20131397","journal-title":"Kidney Int"},{"key":"4042_CR56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.molimm.2013.06.002","volume":"56","author":"AM Lesher","year":"2013","unstructured":"Lesher AM, Nilsson B, Song WC (2013) Properdin in complement activation and tissue injury. Mol Immunol 56:191\u2013198","journal-title":"Mol Immunol"},{"key":"4042_CR57","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.4049\/jimmunol.130.6.2821","volume":"130","author":"E Fischer","year":"1983","unstructured":"Fischer E, Kazatchkine MD (1983) Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement. J Immunol 130:2821\u20132824","journal-title":"J Immunol"},{"key":"4042_CR58","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1073\/pnas.73.2.612","volume":"73","author":"RG Medicus","year":"1976","unstructured":"Medicus RG, Schreiber RD, Gotze O, Muller-Eberhard HJ (1976) A molecular concept of the properdin pathway. Proc Natl Acad Sci US A 73:612\u2013616","journal-title":"Proc Natl Acad Sci US A"},{"key":"4042_CR59","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.4049\/jimmunol.179.4.2600","volume":"179","author":"D Spitzer","year":"2007","unstructured":"Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE (2007) Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol 179:2600\u20132608","journal-title":"J Immunol"},{"key":"4042_CR60","doi-asserted-by":"publisher","first-page":"9023","DOI":"10.1073\/pnas.0801015105","volume":"105","author":"C Kemper","year":"2008","unstructured":"Kemper C, Mitchell LM, Zhang L, Hourcade DE (2008) The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proc Natl Acad Sci US A 105:9023\u20139028","journal-title":"Proc Natl Acad Sci US A"},{"key":"4042_CR61","doi-asserted-by":"publisher","first-page":"F1397","DOI":"10.1152\/ajprenal.90313.2008","volume":"295","author":"H Gaarkeuken","year":"2008","unstructured":"Gaarkeuken H, Siezenga MA, Zuidwijk K, van Kooten C, Rabelink TJ, Daha MR, Berger SP (2008) Complement activation by tubular cells is mediated by properdin binding. Am J Physiol Renal Physiol 295:F1397\u2013F1403","journal-title":"Am J Physiol Renal Physiol"},{"key":"4042_CR62","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2007-05-089821","volume":"111","author":"Y Kimura","year":"2008","unstructured":"Kimura Y, Miwa T, Zhou L, Song WC (2008) Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 111:732\u2013740","journal-title":"Blood"},{"key":"4042_CR63","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4049\/jimmunol.0903598","volume":"185","author":"S Agarwal","year":"2010","unstructured":"Agarwal S, Ferreira VP, Cortes C, Pangburn MK, Rice PA, Ram S (2010) An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J Immunol 185:507\u2013516","journal-title":"J Immunol"},{"key":"4042_CR64","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.imbio.2010.02.002","volume":"215","author":"VP Ferreira","year":"2010","unstructured":"Ferreira VP, Cortes C, Pangburn MK (2010) Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology 215:932\u2013940","journal-title":"Immunobiology"},{"key":"4042_CR65","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1128\/IAI.00980-10","volume":"79","author":"C Cortes","year":"2011","unstructured":"Cortes C, Ferreira VP, Pangburn MK (2011) Native properdin binds to Chlamydia pneumoniae and promotes complement activation. Infect Immun 79:724\u2013731","journal-title":"Infect Immun"},{"key":"4042_CR66","doi-asserted-by":"crossref","unstructured":"Agarwal S, Specht CA, Haibin H, Ostroff GR, Ram S, Rice PA, Levitz SM (2011) Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. mBio 2: pii: e00178-11","DOI":"10.1128\/mBio.00178-11"},{"key":"4042_CR67","doi-asserted-by":"publisher","first-page":"6457","DOI":"10.4049\/jimmunol.1300610","volume":"190","author":"G Saggu","year":"2013","unstructured":"Saggu G, Cortes C, Emch HN, Ramirez G, Worth RG, Ferreira VP (2013) Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol 190:6457\u20136467","journal-title":"J Immunol"},{"key":"4042_CR68","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1074\/jbc.M110.167825","volume":"286","author":"A Zaferani","year":"2011","unstructured":"Zaferani A, Vives RR, van der Pol P, Hakvoort JJ, Navis GJ, van Goor H, Daha MR, Lortat-Jacob H, Seelen MA, van den Born J (2011) Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease. J Biol Chem 286:5359\u20135367","journal-title":"J Biol Chem"},{"key":"4042_CR69","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1159\/000356980","volume":"6","author":"J O'Flynn","year":"2014","unstructured":"O'Flynn J, Dixon KO, Faber Krol MC, Daha MR, van Kooten C (2014) Myeloperoxidase directs properdin-mediated complement activation. J Innate Immun 6:417\u2013425","journal-title":"J Innate Immun"},{"key":"4042_CR70","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1042\/bj2430507","volume":"243","author":"TC Farries","year":"1987","unstructured":"Farries TC, Finch JT, Lachmann PJ, Harrison RA (1987) Resolution and analysis of \u2018native\u2019 and \u2018activated\u2019 properdin. Biochem J 243:507\u2013517","journal-title":"Biochem J"},{"key":"4042_CR71","doi-asserted-by":"publisher","first-page":"E534","DOI":"10.1073\/pnas.1612385114","volume":"114","author":"M Harboe","year":"2017","unstructured":"Harboe M, Johnson C, Nymo S, Ekholt K, Schjalm C, Lindstad JK, Pharo A, Hellerud BC, Nilsson Ekdahl K, Mollnes TE, Nilsson PH (2017) Properdin binding to complement activating surfaces depends on initial C3b deposition. Proc Natl Acadl Sci US A 114:E534\u2013e539","journal-title":"Proc Natl Acadl Sci US A"},{"key":"4042_CR72","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.4049\/jimmunol.1200269","volume":"189","author":"M Harboe","year":"2012","unstructured":"Harboe M, Garred P, Lindstad JK, Pharo A, Muller F, Stahl GL, Lambris JD, Mollnes TE (2012) The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol 189:2606\u20132613","journal-title":"J Immunol"},{"key":"4042_CR73","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-030409-101250","volume":"28","author":"C Kemper","year":"2010","unstructured":"Kemper C, Atkinson JP, Hourcade DE (2010) Properdin: emerging roles of a pattern-recognition molecule. Ann Rev Immunol 28:131\u2013155","journal-title":"Ann Rev Immunol"},{"key":"4042_CR74","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/imr.12466","volume":"274","author":"AZ Blatt","year":"2016","unstructured":"Blatt AZ, Pathan S, Ferreira VP (2016) Properdin: a tightly regulated critical inflammatory modulator. Immunol Rev 274:172\u2013190","journal-title":"Immunol Rev"},{"key":"4042_CR75","doi-asserted-by":"publisher","first-page":"F1308","DOI":"10.1152\/ajprenal.00645.2014","volume":"310","author":"J O'Flynn","year":"2016","unstructured":"O'Flynn J, van der Pol P, Dixon KO, Prohaszka Z, Daha MR, van Kooten C (2016) Monomeric C-reactive protein inhibits renal cell-directed complement activation mediated by properdin. Am J Physiol Renal Physiol 310:F1308\u2013F1316","journal-title":"Am J Physiol Renal Physiol"},{"key":"4042_CR76","doi-asserted-by":"publisher","first-page":"19528","DOI":"10.1074\/jbc.M112.364471","volume":"287","author":"M Hebecker","year":"2012","unstructured":"Hebecker M, Jozsi M (2012) Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein. J Biol Chem 287:19528\u201319536","journal-title":"J Biol Chem"},{"key":"4042_CR77","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.4049\/jimmunol.1403121","volume":"194","author":"AI Csincsi","year":"2015","unstructured":"Csincsi AI, Kopp A, Zoldi M, Banlaki Z, Uzonyi B, Hebecker M, Caesar JJ, Pickering MC, Daigo K, Hamakubo T, Lea SM, Goicoechea de Jorge E, Jozsi M (2015) Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation. J Immunol 194:4963\u20134973","journal-title":"J Immunol"},{"key":"4042_CR78","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1681\/ASN.2015020212","volume":"27","author":"Q Chen","year":"2016","unstructured":"Chen Q, Manzke M, Hartmann A, Buttner M, Amann K, Pauly D, Wiesener M, Skerka C, Zipfel PF (2016) Complement factor H-related 5-hybrid proteins anchor properdin and activate complement at self-surfaces. J Am Soc Nephrol 27:1413\u20131425","journal-title":"J Am Soc Nephrol"},{"key":"4042_CR79","first-page":"412","volume":"3","author":"C Cortes","year":"2012","unstructured":"Cortes C, Ohtola JA, Saggu G, Ferreira VP (2012) Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement. Front Immunol 3:412","journal-title":"Front Immunol"},{"key":"4042_CR80","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1182\/blood-2010-05-283564","volume":"117","author":"L Camous","year":"2011","unstructured":"Camous L, Roumenina L, Bigot S, Brachemi S, Fremeaux-Bacchi V, Lesavre P, Halbwachs-Mecarelli L (2011) Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117:1340\u20131349","journal-title":"Blood"},{"key":"4042_CR81","first-page":"291","volume":"50","author":"AG Sjoholm","year":"1982","unstructured":"Sjoholm AG, Braconier JH, Soderstrom C (1982) Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol 50:291\u2013297","journal-title":"Clin Exp Immunol"},{"key":"4042_CR82","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0161-5890(99)00107-8","volume":"36","author":"CA Fijen","year":"1999","unstructured":"Fijen CA, van den Bogaard R, Schipper M, Mannens M, Schlesinger M, Nordin FG, Dankert J, Daha MR, Sjoholm AG, Truedsson L, Kuijper EJ (1999) Properdin deficiency: molecular basis and disease association. Mol Immunol 36:863\u2013867","journal-title":"Mol Immunol"},{"key":"4042_CR83","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.molimm.2014.06.030","volume":"61","author":"AS Grumach","year":"2014","unstructured":"Grumach AS, Kirschfink M (2014) Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol 61:110\u2013117","journal-title":"Mol Immunol"},{"key":"4042_CR84","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1365-2362.1996.tb02136.x","volume":"26","author":"CA Fijen","year":"1996","unstructured":"Fijen CA, van den Bogaard R, Daha MR, Dankert J, Mannens M, Kuijper EJ (1996) Carrier detection by microsatellite haplotyping in 10 properdin type 1-deficient families. Eur J Clin Investig 26:902\u2013906","journal-title":"Eur J Clin Investig"},{"key":"4042_CR85","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1086\/515075","volume":"28","author":"CA Fijen","year":"1999","unstructured":"Fijen CA, Kuijper EJ, te Bulte MT, Daha MR, Dankert J (1999) Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 28:98\u2013105","journal-title":"Clin Infect Dis"},{"key":"4042_CR86","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1128\/CMR.4.3.359","volume":"4","author":"JE Figueroa","year":"1991","unstructured":"Figueroa JE, Densen P (1991) Infectious diseases associated with complement deficiencies. Clini Microbiol Rev 4:359\u2013395","journal-title":"Clini Microbiol Rev"},{"key":"4042_CR87","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.clim.2009.02.008","volume":"131","author":"L Schejbel","year":"2009","unstructured":"Schejbel L, Rosenfeldt V, Marquart H, Valerius NH, Garred P (2009) Properdin deficiency associated with recurrent otitis media and pneumonia, and identification of male carrier with Klinefelter syndrome. Clin Immunol 131:456\u2013462","journal-title":"Clin Immunol"},{"key":"4042_CR88","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/sj.ejhg.5200496","volume":"8","author":"R Bogaard van den","year":"2000","unstructured":"van den Bogaard R, Fijen CA, Schipper MG, de Galan L, Kuijper EJ, Mannens MM (2000) Molecular characterisation of 10 Dutch properdin type I deficient families: mutation analysis and X-inactivation studies. Eur J Hum Genet 8:513\u2013518","journal-title":"Eur J Hum Genet"},{"key":"4042_CR89","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0162-3109(97)00087-8","volume":"38","author":"L Truedsson","year":"1997","unstructured":"Truedsson L, Westberg J, Fredrikson GN, Sjoholm AG, Kuijper EJ, Fijen CA, Spath PJ, Uhlen M (1997) Human properdin deficiency has a heterogeneous genetic background. Immunopharmacology 38:203\u2013206","journal-title":"Immunopharmacology"},{"key":"4042_CR90","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1365-3083.2012.02674.x","volume":"75","author":"M Helminen","year":"2012","unstructured":"Helminen M, Seitsonen S, Jarva H, Meri S, Jarvela IE (2012) A novel mutation W388X underlying properdin deficiency in a Finnish family. Scand J Immunol 75:445\u2013448","journal-title":"Scand J Immunol"},{"key":"4042_CR91","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1046\/j.1365-2249.1999.01056.x","volume":"118","author":"PJ Spath","year":"1999","unstructured":"Spath PJ, Sjoholm AG, Fredrikson GN, Misiano G, Scherz R, Schaad UB, Uhring-Lambert B, Hauptmann G, Westberg J, Uhlen M, Wadelius C, Truedsson L (1999) Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n). Clin Exp Immunol 118:278\u2013284","journal-title":"Clin Exp Immunol"},{"key":"4042_CR92","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1023\/A:1027385806871","volume":"18","author":"GN Fredrikson","year":"1998","unstructured":"Fredrikson GN, Gullstrand B, Westberg J, Sjoholm AG, Uhlen M, Truedsson L (1998) Expression of properdin in complete and incomplete deficiency: normal in vitro synthesis by monocytes in two cases with properdin deficiency type II due to distinct mutations. J Clin Immunol 18:272\u2013282","journal-title":"J Clin Immunol"},{"key":"4042_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/geno.1995.1208","volume":"29","author":"J Westberg","year":"1995","unstructured":"Westberg J, Fredrikson GN, Truedsson L, Sjoholm AG, Uhlen M (1995) Sequence-based analysis of properdin deficiency: identification of point mutations in two phenotypic forms of an X-linked immunodeficiency. Genomics 29:1\u20138","journal-title":"Genomics"},{"key":"4042_CR94","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJM198807073190106","volume":"319","author":"AG Sjoholm","year":"1988","unstructured":"Sjoholm AG, Kuijper EJ, Tijssen CC, Jansz A, Bol P, Spanjaard L, Zanen HC (1988) Dysfunctional properdin in a Dutch family with meningococcal disease. N Engl J Med 319:33\u201337","journal-title":"N Engl J Med"},{"key":"4042_CR95","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.4049\/jimmunol.157.8.3666","volume":"157","author":"GN Fredrikson","year":"1996","unstructured":"Fredrikson GN, Westberg J, Kuijper EJ, Tijssen CC, Sjoholm AG, Uhlen M, Truedsson L (1996) Molecular characterization of properdin deficiency type III: dysfunction produced by a single point mutation in exon 9 of the structural gene causing a tyrosine to aspartic acid interchange. J Immunol 157:3666\u20133671","journal-title":"J Immunol"},{"key":"4042_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014596","volume":"7","author":"IML Ahout","year":"2017","unstructured":"Ahout IML, Brand KH, Zomer A, van den Hurk WH, Schilders G, Brouwer ML, Neeleman C, Groot R, Ferwerda G (2017) Prospective observational study in two Dutch hospitals to assess the performance of inflammatory plasma markers to determine disease severity of viral respiratory tract infections in children. BMJ Open 7:e014596. https:\/\/doi.org\/10.1136\/bmjopen-2016-014596","journal-title":"BMJ Open"},{"key":"4042_CR97","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.healun.2017.07.006","volume":"37","author":"GM Marron-Linares","year":"2017","unstructured":"Marron-Linares GM, Nunez L, Crespo-Leiro MG, Barge-Caballero E, Pombo J, Paniagua-Martin MJ, Suarez-Fuentetaja N, Cid J, Grille-Cancela Z, Muniz-Garcia J, Tan CD, Rodriguez ER, Vazquez-Rodriguez JM, Hermida-Prieto M (2017) Polymorphisms in genes related to the complement system and antibody-mediated cardiac allograft rejection. J Heart Lung Transplant 37:477\u2013485","journal-title":"J Heart Lung Transplant"},{"key":"4042_CR98","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1160\/th15-05-0439","volume":"115","author":"E Hertle","year":"2016","unstructured":"Hertle E, Arts IC, van der Kallen CJ, Feskens EJ, Schalkwijk CG, Stehouwer CD, van Greevenbroek MM (2016) The alternative complement pathway is longitudinally associated with adverse cardiovascular outcomes. The CODAM study. Thromb Haemost 115:446\u2013457","journal-title":"Thromb Haemost"},{"key":"4042_CR99","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.4049\/jimmunol.1401819","volume":"195","author":"Y Wang","year":"2015","unstructured":"Wang Y, Miwa T, Ducka-Kokalari B, Redai IG, Sato S, Gullipalli D, Zangrilli JG, Haczku A, Song WC (2015) Properdin contributes to allergic airway inflammation through local C3a generation. J Immunol 195:1171\u20131181","journal-title":"J Immunol"},{"key":"4042_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096371","volume":"9","author":"D Pauly","year":"2014","unstructured":"Pauly D, Nagel BM, Reinders J, Killian T, Wulf M, Ackermann S, Ehrenstein B, Zipfel PF, Skerka C, Weber BH (2014) A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS One 9:e96371","journal-title":"PLoS One"},{"key":"4042_CR101","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.4049\/jimmunol.1202275","volume":"190","author":"T Miwa","year":"2013","unstructured":"Miwa T, Sato S, Gullipalli D, Nangaku M, Song WC (2013) Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice. J Immunol 190:3552\u20133559","journal-title":"J Immunol"},{"key":"4042_CR102","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/ki.2014.103","volume":"86","author":"J Miao","year":"2014","unstructured":"Miao J, Lesher AM, Miwa T, Sato S, Gullipalli D, Song WC (2014) Tissue-specific deletion of Crry from mouse proximal tubular epithelial cells increases susceptibility to renal ischemia-reperfusion injury. Kidney Int 86:726\u2013737","journal-title":"Kidney Int"},{"key":"4042_CR103","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1172\/JCI41782","volume":"120","author":"Y Kimura","year":"2010","unstructured":"Kimura Y, Zhou L, Miwa T, Song WC (2010) Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. J Clin Invest 120:3545\u20133554","journal-title":"J Clin Invest"},{"key":"4042_CR104","doi-asserted-by":"publisher","first-page":"E415","DOI":"10.1073\/pnas.1119000109","volume":"109","author":"HF Zhou","year":"2012","unstructured":"Zhou HF, Yan H, Stover CM, Fernandez TM, Rodriguez de Cordoba S, Song WC, Wu X, Thompson RW, Schwaeble WJ, Atkinson JP, Hourcade DE, Pham CT (2012) Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm. Proc Natl Acad Sci U S A 109:E415\u2013E422","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4042_CR105","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1681\/ASN.2017121244","volume":"29","author":"Y Ueda","year":"2018","unstructured":"Ueda Y, Miwa T, Gullipalli D, Sato S, Ito D, Kim H, Palmer M, Song WC (2018) Blocking properdin prevents complement-mediated hemolytic uremic syndrome and systemic thrombophilia. J Am Soc Nephrol 29:1928\u20131937","journal-title":"J Am Soc Nephrol"},{"key":"4042_CR106","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cei.12922","volume":"188","author":"U Jain","year":"2017","unstructured":"Jain U, Midgen CA, Woodruff TM, Schwaeble WJ, Stover CM, Stadnyk AW (2017) Properdin deficiency protects from 5-fluorouracil-induced small intestinal mucositis in a complement activation-independent, interleukin-10-dependent mechanism. Clin Exp Immunol 188:36\u201344","journal-title":"Clin Exp Immunol"},{"key":"4042_CR107","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.4049\/jimmunol.180.10.6962","volume":"180","author":"ND Ivanovska","year":"2008","unstructured":"Ivanovska ND, Dimitrova PA, Luckett JC, El-Rachkidy Lonnen R, Schwaeble WJ, Stover CM (2008) Properdin deficiency in murine models of nonseptic shock. J Immunol 180:6962\u20136969","journal-title":"J Immunol"},{"key":"4042_CR108","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00430-013-0324-z","volume":"203","author":"A Dupont","year":"2014","unstructured":"Dupont A, Mohamed F, Salehen N, Glenn S, Francescut L, Adib R, Byrne S, Brewin H, Elliott I, Richards L, Dimitrova P, Schwaeble W, Ivanovska N, Kadioglu A, Machado LR, Andrew PW, Stover C (2014) Septicaemia models using Streptococcus pneumoniae and Listeria monocytogenes: understanding the role of complement properdin. Med Microbiol Immunol 203:257\u2013271","journal-title":"Med Microbiol Immunol"},{"key":"4042_CR109","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1681\/ASN.2012060570","volume":"24","author":"AM Lesher","year":"2013","unstructured":"Lesher AM, Zhou L, Kimura Y, Sato S, Gullipalli D, Herbert AP, Barlow PN, Eberhardt HU, Skerka C, Zipfel PF, Hamano T, Miwa T, Tung KS, Song WC (2013) Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol 24:53\u201365","journal-title":"J Am Soc Nephrol"},{"key":"4042_CR110","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molimm.2005.06.015","volume":"43","author":"PF Zipfel","year":"2006","unstructured":"Zipfel PF, Heinen S, Jozsi M, Skerka C (2006) Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 43:97\u2013106","journal-title":"Mol Immunol"},{"key":"4042_CR111","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1600-065X.2008.00641.x","volume":"223","author":"VM Holers","year":"2008","unstructured":"Holers VM (2008) The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 223:300\u2013316","journal-title":"Immunol Rev"},{"key":"4042_CR112","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","volume":"66","author":"M Noris","year":"2015","unstructured":"Noris M, Remuzzi G (2015) Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am J Kidney Dis 66:359\u2013375","journal-title":"Am J Kidney Dis"},{"key":"4042_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2007.03552.x","volume":"151","author":"SR Cordoba de","year":"2008","unstructured":"de Cordoba SR, de Jorge EG (2008) Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 151:1\u201313","journal-title":"Clin Exp Immunol"},{"key":"4042_CR114","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","volume":"67","author":"PF Zipfel","year":"2015","unstructured":"Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, Fremeaux-Bacchi V, Nester C, de Cordoba SR, Noris M, Pickering M, Smith R (2015) The role of complement in C3 glomerulopathy. Mol Immunol 67:21\u201330","journal-title":"Mol Immunol"},{"key":"4042_CR115","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grunfeld JP, Niaudet P, Lesavre P, Fremeaux-Bacchi V (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82:454\u2013464","journal-title":"Kidney Int"},{"key":"4042_CR116","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000063520","volume":"25","author":"S Tang","year":"2002","unstructured":"Tang S, Lai KN, Sacks SH (2002) Role of complement in tubulointerstitial injury from proteinuria. Kidney Blood Press Res 25:120\u2013126","journal-title":"Kidney Blood Press Res"},{"key":"4042_CR117","doi-asserted-by":"publisher","first-page":"S186","DOI":"10.1097\/01.ASN.0000070032.58017.20","volume":"14","author":"SI Hsu","year":"2003","unstructured":"Hsu SI, Couser WG (2003) Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 14:S186\u2013S191","journal-title":"J Am Soc Nephrol"},{"key":"4042_CR118","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00467-015-3310-4","volume":"32","author":"M Riedl","year":"2017","unstructured":"Riedl M, Thorner P, Licht C (2017) C3 glomerulopathy. Pediatr Nephrol 32:43\u201357","journal-title":"Pediatr Nephrol"},{"key":"4042_CR119","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00467-011-2059-7","volume":"27","author":"DF Lu","year":"2012","unstructured":"Lu DF, Moon M, Lanning LD, McCarthy AM, Smith RJ (2012) Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol 27:773\u2013781","journal-title":"Pediatr Nephrol"},{"key":"4042_CR120","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","volume":"93","author":"AS Bomback","year":"2018","unstructured":"Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D'Agati VD, Appel GB (2018) C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 93:977\u2013985","journal-title":"Kidney Int"},{"key":"4042_CR121","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/ki.2015.227","volume":"88","author":"C Rabasco","year":"2015","unstructured":"Rabasco C, Cavero T, Roman E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernandez-Juarez G, Gonzalez F, Avila A, Baltar JM, Diaz M, Alegre R, Elias S, Anton M, Frutos MA, Pobes A, Blasco M, Martin F, Bernis C, Macias M, Barroso S, de Lorenzo A, Ariceta G, Lopez-Mendoza M, Rivas B, Lopez-Revuelta K, Campistol JM, Mendizabal S, de Cordoba SR, Praga M (2015) Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88:1153\u20131160","journal-title":"Kidney Int"},{"key":"4042_CR122","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","volume":"9","author":"NR Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT (2014) C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clini J Am Soc Nephrol 9:46\u201353","journal-title":"Clini J Am Soc Nephrol"},{"key":"4042_CR123","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","volume":"71","author":"P Iatropoulos","year":"2016","unstructured":"Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G (2016) Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol 71:131\u2013142","journal-title":"Mol Immunol"},{"key":"4042_CR124","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fremeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodriguez de Cordoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT (2013) C3 glomerulopathy: consensus report. Kidney Int 84:1079\u20131089","journal-title":"Kidney Int"},{"key":"4042_CR125","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1681\/ASN.2012111110","volume":"24","author":"MR Daha","year":"2013","unstructured":"Daha MR (2013) Unexpected role for properdin in complement C3 glomerulopathies. J Am Soc Nephrol 24:5\u20137","journal-title":"J Am Soc Nephrol"},{"key":"4042_CR126","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0272-6386(12)81018-3","volume":"16","author":"WS Varade","year":"1990","unstructured":"Varade WS, Forristal J, West CD (1990) Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III. Am J Kidney Dis 16:196\u2013206","journal-title":"Am J Kidney Dis"},{"key":"4042_CR127","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/0090-1229(90)90144-F","volume":"56","author":"Y Tanuma","year":"1990","unstructured":"Tanuma Y, Ohi H, Hatano M (1990) Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF. Clin Immunol Immunopathol 56:226\u2013238","journal-title":"Clin Immunol Immunopathol"},{"key":"4042_CR128","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0090-1229(89)90141-4","volume":"50","author":"CW Clardy","year":"1989","unstructured":"Clardy CW, Forristal J, Strife CF, West CD (1989) A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clin Immunol Immunopathol 50:333\u2013347","journal-title":"Clin Immunol Immunopathol"},{"key":"4042_CR129","first-page":"73","volume":"65","author":"TE Mollnes","year":"1986","unstructured":"Mollnes TE, Ng YC, Peters DK, Lea T, Tschopp J, Harboe M (1986) Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clin Exp Immunol 65:73\u201379","journal-title":"Clin Exp Immunol"},{"key":"4042_CR130","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ki.2012.250","volume":"82","author":"D Paixao-Cavalcante","year":"2012","unstructured":"Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L, Giclas PC, Goodship TH, de Cordoba SR, Truedsson L, Morgan BP, Harris CL (2012) Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 82:1084\u20131092","journal-title":"Kidney Int"},{"key":"4042_CR131","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1681\/ASN.2017030258","volume":"29","author":"P Iatropoulos","year":"2018","unstructured":"Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, Bresin E, Gamba S, Alberti M, Breno M, Perna A, Bettoni S, Sabadini E, Murer L, Vivarelli M, Noris M, Remuzzi G (2018) Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex-mediated membranoproliferative GN. J Am Soc Nephrol 29:283\u2013294","journal-title":"J Am Soc Nephrol"},{"key":"4042_CR132","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654\u2013666","journal-title":"N Engl J Med"},{"key":"4042_CR133","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676\u20131687","journal-title":"N Engl J Med"},{"key":"4042_CR134","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554\u2013562","journal-title":"Clin J Am Soc Nephrol"},{"key":"4042_CR135","doi-asserted-by":"publisher","first-page":"E1445","DOI":"10.1002\/humu.21256","volume":"31","author":"TK Maga","year":"2010","unstructured":"Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31:E1445\u2013E1460","journal-title":"Hum Mutat"},{"key":"4042_CR136","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844\u20131859","journal-title":"Clin J Am Soc Nephrol"},{"key":"4042_CR137","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1681\/ASN.2004050380","volume":"16","author":"MA Dragon-Durey","year":"2005","unstructured":"Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Fremeaux-Bacchi V (2005) Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:555\u2013563","journal-title":"J Am Soc Nephrol"},{"key":"4042_CR138","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2215\/CJN.01260212","volume":"8","author":"J Hofer","year":"2013","unstructured":"Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Wurzner R, Jungraithmayr T (2013) Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 8:407\u2013415","journal-title":"Clin J Am Soc Nephrol"},{"key":"4042_CR139","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","volume":"339","author":"G Remuzzi","year":"1998","unstructured":"Remuzzi G, Bertani T (1998) Pathophysiology of progressive nephropathies. N Engl J Med 339:1448\u20131456","journal-title":"N Engl J Med"},{"key":"4042_CR140","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1681\/ASN.2006040377","volume":"17","author":"M Abbate","year":"2006","unstructured":"Abbate M, Zoja C, Remuzzi G (2006) How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17:2974\u20132984","journal-title":"J Am Soc Nephrol"},{"key":"4042_CR141","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1471-2369-15-82","volume":"15","author":"S Nagamachi","year":"2014","unstructured":"Nagamachi S, Ohsawa I, Suzuki H, Sato N, Inoshita H, Hisada A, Honda D, Shimamoto M, Shimizu Y, Horikoshi S, Tomino Y (2014) Properdin has an ascendancy over factor H regulation in complement-mediated renal tubular damage. BMC Nephrol 15:82","journal-title":"BMC Nephrol"},{"key":"4042_CR142","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/ki.1994.247","volume":"46","author":"S Ichida","year":"1994","unstructured":"Ichida S, Yuzawa Y, Okada H, Yoshioka K, Matsuo S (1994) Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 46:89\u201396","journal-title":"Kidney Int"},{"key":"4042_CR143","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/ndt\/gfp630","volume":"25","author":"MA Siezenga","year":"2010","unstructured":"Siezenga MA, van der Geest RN, Mallat MJ, Rabelink TJ, Daha MR, Berger SP (2010) Urinary properdin excretion is associated with intrarenal complement activation and poor renal function. Nephrol Dial Transplant 25:1157\u20131161","journal-title":"Nephrol Dial Transplant"},{"key":"4042_CR144","doi-asserted-by":"publisher","first-page":"31471","DOI":"10.1074\/jbc.M112.380386","volume":"287","author":"A Zaferani","year":"2012","unstructured":"Zaferani A, Vives RR, van der Pol P, Navis GJ, Daha MR, van Kooten C, Lortat-Jacob H, Seelen MA, van den Born J (2012) Factor H and properdin recognize different epitopes on renal tubular epithelial heparan sulfate. J Biol Chem 287:31471\u201331481","journal-title":"J Biol Chem"},{"key":"4042_CR145","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0161-5890(00)00047-X","volume":"37","author":"R Gupta-Bansal","year":"2000","unstructured":"Gupta-Bansal R, Parent JB, Brunden KR (2000) Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol 37:191\u2013201","journal-title":"Mol Immunol"},{"key":"4042_CR146","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643\u2013657","journal-title":"Nat Rev Nephrol"},{"key":"4042_CR147","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181","journal-title":"N Engl J Med"},{"key":"4042_CR148","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","volume":"72","author":"M Quintrec Le","year":"2018","unstructured":"Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, Daugas E, Decramer S, Tricot L, Cailliez M, Dubot P, Servais A, Mourey-Epron C, Pourcine F, Loirat C, Fremeaux-Bacchi V, Fakhouri F (2018) Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis 72:84\u201392","journal-title":"Am J Kidney Dis"},{"key":"4042_CR149","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1055\/s-0034-1375299","volume":"40","author":"M Vivarelli","year":"2014","unstructured":"Vivarelli M, Emma F (2014) Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost 40:472\u2013477","journal-title":"Semin Thromb Hemost"},{"key":"4042_CR150","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","volume":"13","author":"A Dmytrijuk","year":"2008","unstructured":"Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R (2008) FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 13:993\u20131000","journal-title":"Oncologist"},{"key":"4042_CR151","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.molimm.2012.10.044","volume":"54","author":"S Heinen","year":"2013","unstructured":"Heinen S, Pluthero FG, van Eimeren VF, Quaggin SE, Licht C (2013) Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol 54:84\u201388","journal-title":"Mol Immunol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4042-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4042-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4042-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T14:26:14Z","timestamp":1693837574000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4042-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":151,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["4042"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4042-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,23]]},"assertion":[{"value":"18 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest. Dr. N. van de Kar is a member of the International aHUS Advisory Board of Alexion. This affiliation had no influence on the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}